New hope for tough bone cancer: immune therapy trial for kids and young adults
NCT ID NCT03006848
Summary
This study tested whether a drug called avelumab could help control a rare and aggressive bone cancer called osteosarcoma when it comes back after standard treatment. It involved 19 patients aged 12 to 50 whose cancer had returned or worsened. The main goals were to see if the drug could shrink tumors and stop the cancer from growing for at least 16 weeks, while carefully tracking side effects and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
St Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
-
Texas Children's Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.